Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347–57.

Article  CAS  PubMed  Google Scholar 

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.

Article  CAS  PubMed  Google Scholar 

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205:22–9.

Article  PubMed  Google Scholar 

McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S. Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health. 2018;21:1259–68.

Article  PubMed  Google Scholar 

Fang M, Nakazawa M, Antonarakis ES, Li C. Efficacy of abiraterone and enzalutamide in pre-and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis. Prostate Cancer. 2017;2017:8560827.

Article  PubMed  PubMed Central  Google Scholar 

Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or enzalutamide in advanced castration‐resistant prostate cancer: an indirect comparison. Prostate. 2017;77:639–46.

Article  CAS  PubMed  Google Scholar 

Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26:743–50.

Article  CAS  PubMed  Google Scholar 

Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB. Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line Abiraterone. JAMA Netw Open. 2022;5:e2142093.

Article  PubMed  PubMed Central  Google Scholar 

Scailteux L-M, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014–2018 French population study (the SPEAR Cohort). Am J Epidemiol. 2021;190:413–22.

Article  PubMed  Google Scholar 

Lin Y-T, Huang Y-C, Liu C-K, Lee T-S, Chen M, Chien Y-N. Treatment-emergent co-morbidities and survival in patients with metastatic castration-resistant prostate cancer receiving abiraterone or enzalutamide. Front Pharm. 2021;12:669236.

Article  CAS  Google Scholar 

Li P-Y, Lu Y-H, Chen C-Y. Comparative effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan. Front Oncol. 2022;12:822375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demirci A, Bilir C, Gülbağcı B, Hacıbekiroğlu İ, Bayoğlu İV, Bilgetekin İ, et al. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Sci Rep. 2021;11:14131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, et al. Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Int J Cancer. 2023;152:1191–201.

Article  CAS  PubMed  Google Scholar 

Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry. Target Oncol. 2020;15:301–15.

Article  PubMed  PubMed Central  Google Scholar 

Anton A, Pillai S, Semira MC, Wong S, Shapiro J, Weickhardt A, et al. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI Compass. 2022;3:205–13.

Article  PubMed  Google Scholar 

Al-Ali BM, Eredics K, Madersbacher S, Schauer I. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer. Wien Klin Wochenschr. 2018;130:659–64.

Article  CAS  PubMed  Google Scholar 

Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, et al. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: a retrospective propensity score–weighted comparative cohort study. Eur J Cancer. 2021;152:215–22.

Article  CAS  PubMed  Google Scholar 

Baillie K, Mueller T, Pan J, Laskey J, Bennie M, Crearie C, et al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiol Drug Saf. 2020;29:653–63.

Article  PubMed  PubMed Central  Google Scholar 

Das P, Taylor S, Price J, Jones M, Martin-Fernandez C, Ali A, et al. Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: a retrospective study of real-world data (ACES). BJUI Compass. 2020;1:21–31.

Article  PubMed  PubMed Central  Google Scholar 

Alkan A, Güç ZG, Gürbüz M, Özgün G, Değirmencioğlu S, Doğan M, et al. Enzalutamide versus abiraterone acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients. J Mens Health 2021;17:128–34.

Google Scholar 

National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. 2023. https://seer.cancer.gov/statfacts/html/prost.html.

Clark R, Vesprini D, Narod SA. The effect of age on prostate cancer survival. Cancers (Basel). 2022;14:4149.

Article  PubMed  Google Scholar 

Centers for Medicare & Medicaid Services. Medicare and You Handbook. Baltimore, MD: U.S. Department of Health & Human Services; 2023.

Fizazi K, Tran N, Fein LE, Matsubara N, Rodríguez Antolín A, Alekseev BY, et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Abstracts of the 2017 ASCO Annual Meeting II. J Clin Oncol. 2017;35:LBA3–LBA3.

Article  Google Scholar 

Banna GL, Urzia V, Benanti C, Pitrè A, Lipari H, Di Quattro R, et al. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Support Care Cancer. 2020;28:4687–95.

Article  PubMed  Google Scholar 

Briones Carvajal JR, Naimi MF, Zhang L, Emmenegger U. Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC). Abstracts of the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium. J Clin Oncol. 2021;39:133.

Article  Google Scholar 

Cuzick J, Sasieni P. Interpreting the results of noninferiority trials—a review. Br J Cancer. 2022;127:1755–9.

Article  PubMed  PubMed Central  Google Scholar 

Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17–24.

Article  PubMed  Google Scholar 

Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77:158–66.

Article  CAS  PubMed  Google Scholar 

Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, et al. Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clin Genitourin Cancer. 2019;17:457–63.e456.

Article  PubMed  Google Scholar 

Riekhof F, Yan Y, Bennett CL, Sanfilippo KM, Carson KR, Chang S-H, et al. Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide. Clin Genitourin Cancer. 2023;S1558-7673:00173–8.

Google Scholar 

George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021;25:524–30.

Article  PubMed  PubMed Central  Google Scholar 

George DJ, Halabi S, Fleming MT, Heath EI, Tutrone RF, Sutton L, et al. A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Abstracts of the 2023 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2023;41:5015.

Article  Google Scholar 

Cheranda N, Luo S, Sanfilippo KM, Eisen SA, Schoen MW. Survival in Black and non-Black patients with metastatic prostate cancer. Abstracts of the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. J Clin Oncol. 2023;41:101.

Article  Google Scholar 

George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–94.

Article  PubMed  Google Scholar